Simvastatin therapy in climacteric women with atherogenic dyslipoproteinemias
Abstract
The study aimed to assess real-world clinical practice effectiveness and safety of simvastatin therapy in climacteric women. A prospective cohort study included 82post-menopausal women with lipid-lowering therapy indications; median age 56,5 (52,0-60,0) years. Simvastatin therapy lasted for one year. After three months of the treatment, total cholesterol (TCH) level significantly reduced, due to decreased low-density lipoprotein (LDL) CH, athemgenicity index decreased, and high to low-density lipoprotein CH ratio increased. Levels of triglycerides and high-density lipoprotein CH remained the same, as well as liver enzyme activity. Neuro-vegetative symptoms of climacteric syndrome become less manifested. Ln climacteric women, long-term simvastatin therapy controlled lipid metabolism effectively and safely.
About the Authors
N. V. Izmozherova
Уральская государственная медицинская академия Росздрава
Russian Federation
Russian Federation
A. A. Popov
Уральская государственная медицинская академия Росздрава
Russian Federation
Russian Federation
References
1. Агеев Ф.Т., Нуралиев Э.Ю., Чернина Г.В. и др. Контролируемое применение симвастатина и «обычная» терапия гиперлипидемии у больных с ишемической болезнью сердца в амбулаторных условиях: сравнительное исследование двух стратегий (СИГНАЛ -КОНТРОЛЬ). Кардиология 2006; 6: 10-15.
2. Кухарчук В.В., Аронов Д.М., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. // Кардиоваскулярная терапия и профилактика. 2004. Т. 3. № S2.
3. Сметник В.П., Кулаков В.И. (ред.). Руководство по климактерию. М.: Медицинское информационное агентство, 2001. 685 с.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9): 7-22.
5. Hully S., Grady D., Bush Т., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-613.
6. Lemay A., Dodin S., Turcot L., et al. Estrogen/progesterone replacement versus pravastatin and the sequentional association in hypercholesterolemic postmenopausal women. Maturitas 2001; 40: 247-257.
7. Ozsener S., Sendag R., Кос Т., et al. A comparison of continuous combined hormone replacement therapy, HMG CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. J Obstet Gynaecol Res 2001; 27: 353-358.
8. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
9. Shepherd J., Packard C., Littlejohn T.W., et al. Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapy. Curr Med Res Opin 2004; 20 (1): 1571-1578.
10. Silverman S.L., Delmas P.D., Kulkarni P.M., et al. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 2004; 52,(9): 1543-1548.
11. Tremollieres P.A., Pouilles J-M., Cauneille C. et al. Coronary heart disease risk factors and menopause: a study in 1684 Prench women. Atherosclerosis 1999; 142: 415-423.
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
Review
For citations:
Izmozherova N.V., Popov A.A. Simvastatin therapy in climacteric women with atherogenic dyslipoproteinemias. Russian Journal of Cardiology. 2008;(2):40-42. (In Russ.)
Views:
318
Email this article 